Diabetes begins as a metabolic syndrome that features a combination of hormonal and nutritional imbalances. If these imbalances aren’t corrected, a pre-diabetic condition can turn into full-fledged diabetes. These hormonal imbalances can result in an inability for your body to produce the insulin that it needs to convert glucose into energy, a condition that is known as insulin resistance. When this occurs, your blood glucose levels will elevate, and you may experience complications and symptoms of diabetes. Likewise, if you suffer from glucose intolerance you may experience low blood sugar when your body doesn’t have enough glucose to use for fuel.
Tandem is in partnership with the JDRF to develop a dual hormone pump which will continue to be funded, as Tandem reaches different milestones. Once approved by the FDA, this novel and groundbreaking medical device will have two hormone chambers. One chamber for insulin, the second chamber for a different hormone that supports different therapies. “At this time, insulin is the only approved hormone for an insulin pump,” says Susan Morrison, Chief Administrative Officer from Tandem Diabetes Care.
In the healthcare field today, perhaps no area holds as much promise and as many perils as weight control. Researchers see the same statistics that the rest of us do. They see the upcoming wave of obesity and diabetes diagnoses. They see the myriad complications that spring up from these conditions. And they want to address the problem in a simple way.
Could a "bionic pancreas"-a combination of insulin pump, continuous glucose monitor and predictive software-be on the market within four years? That 2017 date is the ambitious goal of a project from researchers at Boston University and Massachusetts General Hospital.
Researchers in Taipei, Taiwan, report that they have identified the top three drugs for reducing A1C levels in type 2 diabetes: biphasic insulin, GLP-1 analogs, and basal insulin. They hedged a little on their endorsement of GLP-1 analogs, however, by saying that although they are not decisively better at controlling A1Cs than other oral diabetes drugs, they have the advantage of helping to reduce weight without adding to the danger of hypoglycemia.
The FDA has approved US sales of JANUMET® XR, a daily oral treatment for type 2 diabetes that combines sitagliptin and extended-release metformin. The drug is the fourth oral type 2 diabetes treatment introduced by Merck, which also sells JANUVIA, JANUMET, and JUVISYNC.
Diabetes Health is the essential resource for people living with diabetes- both newly diagnosed and experienced as well as the professionals who care for them. We provide balanced expert news and information on living healthfully with diabetes. Each issue includes cutting-edge editorial coverage of new products, research, treatment options, and meaningful lifestyle issues.
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.